|
KMID : 1145520220080020157
|
|
Journal of Radiopharmaceuticals and Molecular Probes
2022 Volume.8 No. 2 p.157 ~ p.166
|
|
|
Recent Progress in Alpha-emitting Radiopharmaceutical Development for Clinical Application
|
|
Kang Choong-Mo
Choe Yearn-Seong
|
|
|
Abstract
|
|
|
|
Targeted alpha therapy began to be applied to the treatment of late-stage cancer patients because of its dramatic therapeutic efficacy in patients who have no responses with beta-emitting radiopharmaceuticals. However, its strong cytotoxicity may cause side effects due to undesirable uptake in non-target tissues. In order to use alpha-emitting radiopharmaceuticals for early-stage patients as well as late-stage cancer patients, therefore, modifications on their chemical structures are required. In this review, the recent progress in the development of alpha-emitting radiopharmaceuticals is discussed.
|
|
|
KEYWORD
|
|
|
Targeted alpha therapy, Alpha-emitting radiopharmaceuticals, Cancer, Pretargeted radioimmunotherapy, Radioimmunotherapy, Side effect
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|